Business Wire

World First at Maria Middelares Hospital in Belgium Thanks to da Vinci SP’s Innovative Technology

29.5.2024 15:37:00 EEST | Business Wire | Press release

Share

As part of the new Health Value Space Ghent, Maria Middelares Hospital continues to lead the way as a “smart” hospital, poised to deliver healthcare of the future to its patients. The new da Vinci SP (single port) surgical system has now been in use since May 21, making complex surgery even less invasive, via a single incision. It was on May 27 that a world first took place at the hospital: a kidney autotransplantation assisted by the da Vinci SP surgical system.

The arrival of Intuitive’s new da Vinci SP system aligns perfectly with Maria Middelares' vision of developing a patient-oriented robotics platform. The SP enables more complex procedures to be performed through a single incision or natural orifice. Over 400 peer-reviewed publications demonstrate the safety, efficacy, and excellent results of this cutting-edge technology. The da Vinci SP offers incredible value on a daily basis for Maria Middelares and its patients.

  • A World First

On May 27, urologist Prof. dr. Decaestecker achieved a world first. Using the da Vinci SP, he performed an intracorporeal kidney autotransplantation on an 18-year-old woman suffering from a complex ureteral lesion, with severe damage to the ureter between the kidney and the bladder. The best solution for the patient was to bridge the major defect in the ureter by moving the kidney closer to the bladder. This technique is called autotransplantation.

The transplantation was achieved intracorporeally, meaning entirely inside the body. Prof. dr. Decaestecker has perfected this technique, having performed such operations since 2017 (a European first at the time) using the da Vinci Multiport system, equipped with four robotic arms. The advantage of an in-body operation is that no large incisions are required to move the kidney in and out of the body; only a few small incisions (with the Multiport) of around 1 cm were needed to introduce the robotic instruments.

Prof. dr. Decaestecker explains: What’s new now is the combination of in-body grafting with a single incision thanks to the SP robotic system, which has just one articulated arm. This is less intrusive for the patient’s body and should also facilitate smoother post-op recovery. Other advantages are that we can perform the procedure entirely outside the abdomen, allowing the patient to lie flat on their back in a natural position. This is important as the patient can now be operated on in a more comfortable position, therefore with fewer intestinal complications.”

  • What does the future hold?

With the development of a robotics platform, Maria Middelares aims to optimize the use of robotic systems within the operating room as much as possible. The goal is to improve operating room efficiency and patient outcomes. These innovative surgical systems allow for further personalization of surgery based on patient needs.

Dr. Ameye, Director of Innovation, adds: “In our organization, we strive to seek out the best technology combined with in-depth monitoring. We map the quality of care using big data analysis based on a multitude of uniform data. This enables us to identify areas for improvement and continuously optimize our care. Providing value-based healthcare is our main motivation.”

You can download images from the operating room of this world premiere via this link.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information

Catherine Zenner, Head of Communications Maria Middelares
catherine.zenner@mijnziekenhuis.be or 0478 99 53 11.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye